Volume 66, Issue 5, Pages (November 2014)

Slides:

Advertisements

Similar presentations

Docetaxel +/- zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT )

Advertisements

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive,

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 Silke Gillessen, Gerhardt.

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 378, Issue 9809, Pages (December 2011)

Volume 56, Issue 6, Pages (December 2009)

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 73, Issue 2, Pages (February 2018)

Volume 67, Issue 4, Pages (April 2015)

Volume 54, Issue 6, Pages (December 2008)

Volume 72, Issue 5, Pages (November 2017)

Volume 17, Issue 2, Pages (February 2016)

Volume 69, Issue 1, Pages (January 2016)

Volume 53, Issue 5, Pages (May 2008)

Let the Games Begin (with EAU Approval)

Prostate Cancer Epidemic in Sight?

Volume 72, Issue 5, Pages (November 2017)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Volume 54, Issue 4, Pages (October 2008)

Volume 74, Issue 4, Pages (October 2018)

Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward Takuma Uo, Cynthia Sprenger European Urology

Prostate Cancer Detection: A View of the Future

Volume 74, Issue 1, Pages (July 2018)

Volume 387, Issue 10024, Pages (March 2016)

Volume 66, Issue 3, Pages (September 2014)

Volume 70, Issue 5, Pages (November 2016)

Volume 69, Issue 6, Pages (June 2016)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

James N. Armitage, Stuart O. Irving, Neil A. Burgess European Urology

Yuanshan Cui, Yong Zhang European Urology

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 72, Issue 1, Pages (July 2017)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

The Economic Costs of Overactive Bladder in Germany

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 62, Issue 3, Pages (September 2012)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Volume 15, Issue 4, Pages (April 2014)

Volume 55, Issue 6, Pages (June 2009)

Volume 74, Issue 5, Pages (November 2018)

Volume 71, Issue 3, Pages (March 2017)

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Volume 67, Issue 6, Pages (June 2015)

Testicular Cancer Variations in Time and Space in Europe

Volume 72, Issue 2, Pages (August 2017)

Volume 72, Issue 5, Pages (November 2017)

Volume 10, Issue 9, Pages (September 2009)

Volume 71, Issue 4, Pages (April 2017)

European Urology is “Your” Journal

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 392, Issue 10162, Pages (December 2018)

Volume 378, Issue 9809, Pages (December 2011)

Volume 17, Issue 2, Pages (February 2016)

Volume 13, Issue 5, Pages (May 2012)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Volume 51, Issue 5, Pages (May 2007)

Volume 392, Issue 10162, Pages (December 2018)

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

Presentation transcript:

Volume 66, Issue 5, Pages 799-802 (November 2014) Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial Gerhardt Attard, Matthew R. Sydes, Malcolm D. Mason, Noel W. Clarke, Daniel Aebersold, Johann S. de Bono, David P. Dearnaley, Chris C. Parker, Alastair W.S. Ritchie, J. Martin Russell, George Thalmann, Estelle Cassoly, Robin Millman, David Matheson, Francesca Schiavone, Melissa R. Spears, Mahesh K.B. Parmar, Nicholas D. James European Urology Volume 66, Issue 5, Pages 799-802 (November 2014) DOI: 10.1016/j.eururo.2014.05.038 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Accrual activity over time. SOC=Standard-of-care=ADT (+/−RT); ADT=androgen deprivation therapy; RT=radiotherapy. European Urology 2014 66, 799-802DOI: (10.1016/j.eururo.2014.05.038) Copyright © 2014 European Association of Urology Terms and Conditions